Effectiveness of dupilumab treatment to treat the chronic rhinosinusitis with nasal polyposis: A systematic review and meta-analysi
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease treat...
In the difficult-to-treat subgroup of patients with chronic rhinosinusitis with nasal polyps (CRSwNP...
Objectives/Hypothesis Dupilumab, a fully human monoclonal antibody that blocks the shared interleuki...
Effectiveness of dupilumab treatment to treat the chronic rhinosinusitis with nasal polyposis: A sys...
Jean Kim,1,2 Robert Naclerio1 1Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins Uni...
Biologics are currently one of the main treatment options for a number of diseases. The IgG4 monoclo...
The aim of this study was to evaluate the efficacy of dupilumab in the treatment of severe uncontrol...
Dupilumab has been shown to be safe and effective in treating chronic rhinosinusitis with polyposis ...
The aim of this study was to evaluate the efficacy of dupilumab in the treatment of severe uncontrol...
Abstract Background Dupilumab is the first monoclonal antibody therapy to be approved in Canada for ...
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) represents 25-30% of all CRS cases, an...
Background For patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) which cannot b...
Dupilumab has demonstrated efficacy in patients with asthma and atopic dermatitis, which are both ty...
Background The human monoclonal antibody dupilumab blocks interleukin (IL)-4 andIL-13, key and centr...
IMPORTANCE: Dupilumab has demonstrated efficacy in patients with asthma and atopic dermatitis, which...
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease treat...
In the difficult-to-treat subgroup of patients with chronic rhinosinusitis with nasal polyps (CRSwNP...
Objectives/Hypothesis Dupilumab, a fully human monoclonal antibody that blocks the shared interleuki...
Effectiveness of dupilumab treatment to treat the chronic rhinosinusitis with nasal polyposis: A sys...
Jean Kim,1,2 Robert Naclerio1 1Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins Uni...
Biologics are currently one of the main treatment options for a number of diseases. The IgG4 monoclo...
The aim of this study was to evaluate the efficacy of dupilumab in the treatment of severe uncontrol...
Dupilumab has been shown to be safe and effective in treating chronic rhinosinusitis with polyposis ...
The aim of this study was to evaluate the efficacy of dupilumab in the treatment of severe uncontrol...
Abstract Background Dupilumab is the first monoclonal antibody therapy to be approved in Canada for ...
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) represents 25-30% of all CRS cases, an...
Background For patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) which cannot b...
Dupilumab has demonstrated efficacy in patients with asthma and atopic dermatitis, which are both ty...
Background The human monoclonal antibody dupilumab blocks interleukin (IL)-4 andIL-13, key and centr...
IMPORTANCE: Dupilumab has demonstrated efficacy in patients with asthma and atopic dermatitis, which...
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease treat...
In the difficult-to-treat subgroup of patients with chronic rhinosinusitis with nasal polyps (CRSwNP...
Objectives/Hypothesis Dupilumab, a fully human monoclonal antibody that blocks the shared interleuki...
DOI
Add to ORKG